JP2019502923A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502923A5 JP2019502923A5 JP2018534923A JP2018534923A JP2019502923A5 JP 2019502923 A5 JP2019502923 A5 JP 2019502923A5 JP 2018534923 A JP2018534923 A JP 2018534923A JP 2018534923 A JP2018534923 A JP 2018534923A JP 2019502923 A5 JP2019502923 A5 JP 2019502923A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- antibody
- progastrin
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims description 37
- 101800000285 Big gastrin Proteins 0.000 claims description 31
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 23
- 206010033128 Ovarian cancer Diseases 0.000 claims description 16
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims 5
- 102400000948 Big gastrin Human genes 0.000 claims 3
- 102400000921 Gastrin Human genes 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- FMIHGWZLPSIAFY-WGFKALLTSA-N gastrin-34 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C1=CC=C(O)C=C1 FMIHGWZLPSIAFY-WGFKALLTSA-N 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229940126586 small molecule drug Drugs 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- 231100000632 Spindle poison Toxicity 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003432 anti-folate effect Effects 0.000 claims 1
- 229940127074 antifolate Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 239000004052 folic acid antagonist Substances 0.000 claims 1
- 108010066264 gastrin 17 Proteins 0.000 claims 1
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 claims 1
- 108010017400 glycine-extended gastrin 17 Proteins 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000000649 purine antagonist Substances 0.000 claims 1
- 239000003790 pyrimidine antagonist Substances 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021167961A JP7279761B2 (ja) | 2015-12-31 | 2021-10-13 | 卵巣癌の検出および治療のための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15307192.3 | 2015-12-31 | ||
| EP15307192 | 2015-12-31 | ||
| EP16305138.6 | 2016-02-05 | ||
| EP16305138 | 2016-02-05 | ||
| PCT/EP2017/050033 WO2017114972A1 (en) | 2015-12-31 | 2017-01-02 | Compositions and methods for detecting and treating ovarian cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167961A Division JP7279761B2 (ja) | 2015-12-31 | 2021-10-13 | 卵巣癌の検出および治療のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502923A JP2019502923A (ja) | 2019-01-31 |
| JP2019502923A5 true JP2019502923A5 (enExample) | 2019-06-06 |
| JP6962920B2 JP6962920B2 (ja) | 2021-11-05 |
Family
ID=57821943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534923A Active JP6962920B2 (ja) | 2015-12-31 | 2017-01-02 | 卵巣癌の検出および治療のための組成物および方法 |
| JP2021167961A Active JP7279761B2 (ja) | 2015-12-31 | 2021-10-13 | 卵巣癌の検出および治療のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167961A Active JP7279761B2 (ja) | 2015-12-31 | 2021-10-13 | 卵巣癌の検出および治療のための組成物および方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11760808B2 (enExample) |
| EP (2) | EP3397964B1 (enExample) |
| JP (2) | JP6962920B2 (enExample) |
| KR (2) | KR102507685B1 (enExample) |
| CN (1) | CN108780091A (enExample) |
| AU (2) | AU2017204682B2 (enExample) |
| BR (1) | BR112018013271A2 (enExample) |
| CA (2) | CA3194356C (enExample) |
| EA (1) | EA037015B1 (enExample) |
| ES (2) | ES2901602T3 (enExample) |
| PL (1) | PL3397964T3 (enExample) |
| SG (1) | SG11201805605TA (enExample) |
| WO (1) | WO2017114972A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240018264A1 (en) * | 2015-12-31 | 2024-01-18 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
| EP3720879B1 (en) * | 2017-12-05 | 2022-05-11 | Progastrine et Cancers S.à r.l. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
| AU2018381046B2 (en) | 2017-12-08 | 2025-10-02 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
| TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ｅｃｓ前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
| WO2019166499A1 (en) | 2018-02-27 | 2019-09-06 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
| JP7687224B2 (ja) * | 2022-01-25 | 2025-06-03 | 株式会社三洋物産 | 遊技機 |
| JP7687223B2 (ja) * | 2022-01-25 | 2025-06-03 | 株式会社三洋物産 | 遊技機 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| WO1998046645A2 (en) | 1997-04-14 | 1998-10-22 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | Method for the production of antihuman antigen receptors and uses thereof |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2008513536A (ja) * | 2004-09-22 | 2008-05-01 | レセプター バイオロジックス インコーポレイテッド | プロガストリンに対するモノクローナル抗体 |
| US7854932B2 (en) * | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| WO2008157383A1 (en) | 2007-06-15 | 2008-12-24 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis of ovarian cancer and lung cancer |
| EP2488551B1 (en) * | 2009-10-16 | 2018-07-25 | Progastrine et Cancers S.à r.l. | Monoclonal antibodies to progastrin and their uses |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
| US8900588B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| SG184092A1 (en) * | 2010-03-24 | 2012-10-30 | Biorealites | Prophylaxis of colorectal and gastrointestinal cancer |
| ES2871092T3 (es) | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Métodos y composiciones para la terapia del cáncer de hígado |
-
2017
- 2017-01-02 US US16/067,151 patent/US11760808B2/en active Active
- 2017-01-02 CA CA3194356A patent/CA3194356C/en active Active
- 2017-01-02 PL PL17700480T patent/PL3397964T3/pl unknown
- 2017-01-02 CN CN201780013872.3A patent/CN108780091A/zh active Pending
- 2017-01-02 WO PCT/EP2017/050033 patent/WO2017114972A1/en not_active Ceased
- 2017-01-02 EA EA201891529A patent/EA037015B1/ru unknown
- 2017-01-02 AU AU2017204682A patent/AU2017204682B2/en active Active
- 2017-01-02 BR BR112018013271A patent/BR112018013271A2/pt not_active IP Right Cessation
- 2017-01-02 KR KR1020227022682A patent/KR102507685B1/ko active Active
- 2017-01-02 SG SG11201805605TA patent/SG11201805605TA/en unknown
- 2017-01-02 ES ES17700480T patent/ES2901602T3/es active Active
- 2017-01-02 KR KR1020187020588A patent/KR102428254B1/ko active Active
- 2017-01-02 ES ES21199551T patent/ES3015244T3/es active Active
- 2017-01-02 CA CA3009751A patent/CA3009751A1/en active Pending
- 2017-01-02 JP JP2018534923A patent/JP6962920B2/ja active Active
- 2017-01-02 EP EP17700480.1A patent/EP3397964B1/en active Active
- 2017-01-02 EP EP21199551.9A patent/EP3954999B9/en active Active
-
2021
- 2021-10-11 AU AU2021250840A patent/AU2021250840B2/en active Active
- 2021-10-13 JP JP2021167961A patent/JP7279761B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12139548B2 (en) | Antibody that binds ErbB-2 and ErbB-3 | |
| US20230295300A1 (en) | Antibodies specific to delta 1 chain of t cell receptor | |
| JP2019505785A5 (enExample) | ||
| JP2019502923A5 (enExample) | ||
| JP7274426B2 (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| KR20130043168A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2019505784A5 (enExample) | ||
| US12516133B2 (en) | TGFβ/PD-L1 bispecific binding proteins | |
| CA3156983A1 (en) | Antibodies against the poliovirus receptor (pvr) and uses thereof | |
| JP2023528223A (ja) | 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体 | |
| KR20240150805A (ko) | Sting 효능제를 포함하는 항체 약물 접합체, 조합 및 사용 방법 | |
| US20240052065A1 (en) | Binding molecules for the treatment of cancer | |
| WO2024216028A1 (en) | Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor | |
| US20220169736A1 (en) | Combinations of anti-ildr2 antibodies and pd-1 antagonists | |
| KR20250169623A (ko) | 암 치료를 위한 grem1 길항제를 수반하는 조합 요법 | |
| HK40051621A (en) | Antibody that binds erbb-2 and erbb-3 | |
| HK40051621B (en) | Antibody that binds erbb-2 and erbb-3 | |
| HK40006122A (en) | Antibody that binds erbb-2 and erbb-3 | |
| HK40006122B (en) | Antibody that binds erbb-2 and erbb-3 | |
| NZ724012B2 (en) | Antibody that binds erbb-2 and erbb-3 |